U.S., June 9 -- ClinicalTrials.gov registry received information related to the study (NCT07631611) titled 'Organ-Specific Differences in Immunotherapy Response Among Metastatic Cancer Patients' on May 28.
Brief Summary: This study examines how tumors in different metastatic organs respond to immune checkpoint inhibitor (ICB) therapy in real-world clinical practice. ICB therapy helps the immune system recognize and attack cancer cells, but treatment responses may vary depending on where the cancer has spread. Common metastatic sites such as the liver, brain, lung, and bone each have unique immune environments that may influence treatment outcomes.
The investigators will review the medical records of approximately 1,000 adults with solid t...